Association of Increased Fluvoxamine Use with Reports of Benefit for COVID
Kojima, N.; Qato, D. M.; Klausner, J. D.
Show abstract
IntroductionSeveral recent studies have found that fluvoxamine decreases the risk of serious disease progression among people with early SARS-CoV-2 infection. In this study, we examined changes in the total number of fluvoxamine tablets dispensed across retail pharmacies in the U.S. MethodsWe hypothesized that fluvoxamine prescriptions would increase substantially since March 2021 as an option for the early treatment of SARS-CoV-2 infection. We used the IQVIA National Prescription Audit (NPA) Weekly nationally projected data for prescriptions dispensed from retail pharmacies for fluvoxamine from 27 December 2019 to 31 December 2021. We performed an interrupted-time series analyses on frequency of dispensing fluvoxamine tablets. ResultsThe weekly rate of dispensed tablets of fluvoxamine increased throughout the study period. The weekly number of dispensed tablets of fluvoxamine increased (11.1%) from a baseline of 1,586,154 (95% confidence interval [CI]: 1,563,960 - 1,608,348) to 1,762,381 (95% CI: 1,735,682 - 1,789,080) by December 2021. ConclusionOur findings are consistent with a modest increase in the use of fluvoxamine for the treatment of COVID-19 associated with the discovery and media dissemination of the potential clinical benefit of fluvoxamine use.
Matching journals
The top 14 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 92%
- Sales of over-the-counter products containing codeine in 31 countries, 2013-2019: a retrospective observational study 92%
- Patient-Reported Reasons for Antihypertensive Medication Change: A Quantitative Study Using Social Media 91%
Similar papers in this journal
- Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents Over Three Decades, 1995-2017: Cross-Sectional Analysis 90%
- COVID-SAFER: Deprescribing Guidance for Nirmatrelvir-ritonavir Drug Interactions in Older Adults 90%
- Out-of-Pocket Spending for Health Care Within 90 Days of COVID-19 Hospitalization 89%
Similar papers in this journal
- Real-world observation on response to cholinesterase inhibitors or selective serotonin reuptake inhibitors prescribed to outpatients with dementia using electronic medical records 90%
- Atovaquone for Treatment of COVID-19: A Prospective Randomized, Double-Blind, Placebo-Controlled Clinical Trial 89%
- Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance Study 88%
Similar papers in this journal
- Outpatient antibiotic prescribing and demographic factors associated with state-level septicemia mortality rates in US adults 89%
- Association between SARS-CoV-2 Infection and Select Symptoms and Conditions 31 to 150 Days After Testing among Children and Adults 88%
- Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: A multi-center observational study 87%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.